Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trans-chalcone is a natural small molecule flavonoid and the thermodynamically stable isomer of chalcone, found in various plants. It exhibits a broad spectrum of pharmacological activities, including anti-inflammatory, antioxidant, anticancer, and anthelmintic properties. Mechanistically, it acts as a multi-target modulator of several signaling pathways, primarily activating cytoprotective pathways such as Nrf2, SIRT1, and AMPK, while suppressing pro-inflammatory signaling through the inhibition of NF-κB and the NLRP3 inflammasome. Additionally, trans-chalcone has been identified as a pore blocker for large-conductance calcium-activated potassium (BKCa) channels and an antagonist for nociceptive TRP channels (TRPV1 and TRPA1). Research suggests potential therapeutic applications in metabolic diseases like obesity and NAFLD, neurodegenerative conditions such as Parkinson's disease, cardiovascular injuries, and various cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trans-chalcone.